Author Archives: Guest Blogger

The US Biotech Drug Pricing Challenge

by Tom Norton In the midst of the hue and cry last week over the public release of individual Medicare payments to physicians, I was surprised to read that one of Medicare’s most costly medical services is — ophthalmology.  According to the New York Times: “One of the most heavily reimbursed procedures — costing a […]
Posted in Biotech, Corporate Responsibility, Guest Blog, healthcare, Market Access, pricing, Strategy | Tagged , , , , , , , , | 1 Comment

Biopharmaceuticals: Approvals Rate Best in Five Years

Overall, last year can be considered quite a successful one in terms of new product approvals. Nineteen products containing new biopharmaceutical molecular entities were approved in the United States and/or the European Union. These approval numbers are above average compared to the previous five years, which recorded a mean approval rate of 13 products. The […]
Posted in Biotech, Europe, Global, Guest Blog, Regulatory | Tagged , , | Leave a comment

Getting Value from Big Data

By Julie Miller. Health IT is going through an era of both expansion and convergence, in which the universe of available information is growing exponentially, while at the same time, we’re trying to smash all the resulting data together into dense little packages. It’s kind of like the big-bang theory meets big data. Regardless of […]
Posted in Guest Blog, healthcare, Strategy, Technology | Tagged , , | Leave a comment

Say What? The Doctor-Patient Conversation

by Abby Mansfield We spend a lot of time focusing on what our advertising says to physicians, what our reps say to physicians, and what our websites and various other channels communicate to patients. All are important in the marketing of pharma brands. But there’s another critical communication channel we can’t ignore: the doctor-patient conversation.
Posted in Advertising, Agency Insight, Guest Blog, Marketing, Patient Communication, patient compliance, patient education | Tagged , , , | Leave a comment

European Regulator’s Last Ditch Attempt at Transparency

By Peter O’ Donnell. The European Medicines Agency is determined to minimize opposition to its next moves on releasing clinical trial data. It announced last week yet another consultation on its plans to publish the results of trials — a policy it initially aimed at introducing from the beginning of this year. The latest twist […]
Posted in Europe, Global, Op-Ed, Regulatory | Tagged , , , , | Leave a comment
  • Categories

  • Meta